Results 71 to 80 of about 289,170 (184)

MRI-based radiomic signature for MYCN amplification prediction of pediatric abdominal neuroblastoma [PDF]

Sensors & Diagnostics
MYCN gene amplification critically drives neuroblastoma aggressiveness and poor outcomes, necessitating precise preoperative identification to guide risk-adapted therapies.
Xuan Jia, Junjie Wen, Jiawei Liang, Xiaohui Ma, Wenqi Wang, Jinhu Wang, Yi Zhang   +6 more
doaj   +1 more source

Interventional oncology in children: Where are we now?

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel, Fernando Gómez Muñoz   +1 more
wiley   +1 more source

p53 is a direct transcriptional target of MYCN in neuroblastoma

MYCN amplification occurs in approximately 25% of neuroblastomas, where it is associated with rapid tumor progression and poor prognosis. MYCN plays a paradoxical role in driving cellular proliferation and inducing apoptosis.
Tweddle DA, Gherardi S, Lunec J, Chen L, Wood KM, Iraci N, Perini G, Gamble LD   +7 more
core   +4 more sources

High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene

BMC Genomics, 2008
Background Neuroblastoma is a very heterogeneous pediatric tumor of the sympathetic nervous system showing clinically significant patterns of genetic alterations.
Kogner Per, Abrahamsson Jonas, Sjöberg Rose-Marie, Enerbäck Charlotta, Olsson Linda, Erichsen Jennie, Carén Helena, Martinsson Tommy   +7 more
doaj   +1 more source

Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice

Disease Models & Mechanisms, 2015
Neuroblastoma is characterized by a wide range of clinical manifestations and associated with poor prognosis when there is amplification of MYCN oncogene or high expression of Myc oncoproteins.
Chao-Cheng Huang, Shuo-Yu Wang, Li-Ling Lin, Pei-Wen Wang, Ting-Ya Chen, Wen-Ming Hsu, Tsu-Kung Lin, Chia-Wei Liou, Jiin-Haur Chuang   +8 more
doaj   +1 more source

Interlaboratory performance testing on EPIC v2.0 CNS tumor profiling demonstrates high reproducibility of tumor classification but reveals the need for harmonized copy number variation reporting

Brain Pathology, EarlyView.
Using the Infinium MethylationEPIC v2.0 array and Heidelberg Brain Tumor Classifier v12.8, 24 international laboratories achieved highly reproducible CNS tumor classification (97.9% correct; median β‐correlation r = 0.99), while copy number variation interpretation showed substantial interlaboratory variability, highlighting the need for harmonized CNV
Katrin Mauch‐Mücke, Christin Siewert, Lora Dimitrova, Sandra Pohl, Brendan Osberg, Annika K. Wefers, Julia Lorenz, Tanja Rothhammer‐Hampl, Till Acker, Alonso Barrantes‐Freer, Jean Boutonnat, Bérengère Dadone‐Montaudié, Claire Delbridge, Wolfgang Dietmaier, Sebastian Dintner, Hildegard Dohmen, Matthias Dottermusch, Daniel Erny, Katrin B. M. Frauenknecht, Tobias Goschzik, Patrick N. Harter, Daniela Hirsch, Yanghao Hou, Theo F. J. Kraus, Maggie Lee, Friederike Liesche‐Starnecker, Anne Mc Leer, Linea Melchior, Michael Mittelbronn, Wolf C. Müller, Shalima S. Nair, Julia E. Neumann, Pitt Niehusmann, Nicole Pfarr, Torsten Pietsch, Marco Prinz, Markus Rechsteiner, Regina Reimann, Laveniya Satgunaseelan, Veronica Skarpeteig, Anne J. Skjulsvik, Karl Sotlar, Isabelle Vanden Bempt, Erik Vassella, Katharina J. Weber, Gabriel Wasinger, Andreas Waha, Karen Zwaenepoel, Felix Sahm, Markus J. Riemenschneider, David Capper   +50 more
wiley   +1 more source

p53 is a direct transcriptional target of MYCN in neuroblastoma.

, 2010
MYCN amplification occurs in approximately 25% of neuroblastomas, where it is associated with rapid tumor progression and poor prognosis. MYCN plays a paradoxical role in driving cellular proliferation and inducing apoptosis.
PERINI, GIOVANNI, Lunec J., Tweddle D. A., Iraci N., Gamble L. D., GHERARDI, SAMUELE, Chen L., Wood K. M., Wood KM, Chen LD, Tweddle DA, IRACI, NUNZIO, Gherardi S, Lunec J, Perini G, Gamble LD   +15 more
core   +1 more source

Correction to "Molecular and clinical features of a Japanese medulloblastoma cohort: Subgroup-specific prognostic stratification using economical/accessible diagnostic methods". [PDF]

Brain Pathol
Brain Pathology, EarlyView.
europepmc   +2 more sources

AOSNP‐ADAPTR resource level‐based recommendations on practical diagnostic strategies for medulloblastomas and other embryonal tumors

Brain Pathology, EarlyView.
Resource level‐based recommendations on practical diagnostic strategies for medulloblastomas and other CNS embryonal tumors are provided. Abstract WHO CNS5 mandates integrated histo‐molecular classification of medulloblastomas (MBs) and other CNS embryonal tumors. However, advanced molecular diagnostics remain inaccessible in many low‐ and lower‐middle‐
Chitra Sarkar, Maysa Al‐Hussaini, Vani Santosh, Vaishali Suri, Sung‐Hye Park, Yue‐Shan Piao, Tarik Tihan, Ho‐Keung Ng, Michael Buckland, Rakesh Jalali, Yonehiro Kanemura, Pieter Wesseling, Takashi Komori   +12 more
wiley   +1 more source

Clinical evaluation of the CrossNN DNA methylation classifier for central nervous system tumors

Brain Pathology, EarlyView.
CrossNN demonstrated non‐inferiority to the Heidelberg CNS Tumor Methylation Classifier. A dual‐classifier approach increased the number of clinically informative classifications with correct tumor type assignment while maintaining a low rate of incorrect predictions.
Jonas Dahnoun, Léon C. van Kempen, Senada Koljenović, Ken Op de Beeck, Tomas Menovsky, Bart Feyen, Melek Ahmed, Anne Sieben, Karen Zwaenepoel   +8 more
wiley   +1 more source